Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
Advances in the treatment of malignant pleural mesothelioma (MPM) have been disappointing, despite the apparent need for new therapeutic options for this rare and devastating cancer. Drug resistance is common and surgical intervention has brought benefits only to a subset of patients. MPM is a heter...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.806570/full |
| _version_ | 1819283503729082368 |
|---|---|
| author | Moshe Lapidot Srinivas Vinod Saladi Srinivas Vinod Saladi Ravi Salgia Martin Sattler Martin Sattler |
| author_facet | Moshe Lapidot Srinivas Vinod Saladi Srinivas Vinod Saladi Ravi Salgia Martin Sattler Martin Sattler |
| author_sort | Moshe Lapidot |
| collection | DOAJ |
| description | Advances in the treatment of malignant pleural mesothelioma (MPM) have been disappointing, despite the apparent need for new therapeutic options for this rare and devastating cancer. Drug resistance is common and surgical intervention has brought benefits only to a subset of patients. MPM is a heterogenous disease with a surprisingly low mutation rate and recent sequencing efforts have confirmed alterations in a limited number of tumor suppressors that do not provide apparent insights into the molecular mechanisms that drive this malignancy. There is increasing evidence that epigenetic regulation leads to immune evasion and transformation in MPM. Further, the low efficacy of immune checkpoint inhibitors is consistent with a suppression of genes involved in the anti-tumor immune response. We review three promising emerging therapeutic targets (STAT3, KDM4A, heparanase) and highlight their potential effects on the immune response. |
| first_indexed | 2024-12-24T01:32:31Z |
| format | Article |
| id | doaj.art-e4df075f15054d96adf40693c0b9a970 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-24T01:32:31Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e4df075f15054d96adf40693c0b9a9702022-12-21T17:22:19ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-01-011210.3389/fphar.2021.806570806570Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural MesotheliomaMoshe Lapidot0Srinivas Vinod Saladi1Srinivas Vinod Saladi2Ravi Salgia3Martin Sattler4Martin Sattler5Department of Thoracic Surgery, Galilee Medical Center, Nahariya, IsraelDepartment of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United StatesBroad Institute of Harvard and MIT, Cambridge, MA, United StatesDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United StatesDepartment of Medicine, Harvard Medical School, Boston, MA, United StatesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesAdvances in the treatment of malignant pleural mesothelioma (MPM) have been disappointing, despite the apparent need for new therapeutic options for this rare and devastating cancer. Drug resistance is common and surgical intervention has brought benefits only to a subset of patients. MPM is a heterogenous disease with a surprisingly low mutation rate and recent sequencing efforts have confirmed alterations in a limited number of tumor suppressors that do not provide apparent insights into the molecular mechanisms that drive this malignancy. There is increasing evidence that epigenetic regulation leads to immune evasion and transformation in MPM. Further, the low efficacy of immune checkpoint inhibitors is consistent with a suppression of genes involved in the anti-tumor immune response. We review three promising emerging therapeutic targets (STAT3, KDM4A, heparanase) and highlight their potential effects on the immune response.https://www.frontiersin.org/articles/10.3389/fphar.2021.806570/fullmalignant pleural mesotheliomaSTAT3heparanaseSETD2KDM4A |
| spellingShingle | Moshe Lapidot Srinivas Vinod Saladi Srinivas Vinod Saladi Ravi Salgia Martin Sattler Martin Sattler Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma Frontiers in Pharmacology malignant pleural mesothelioma STAT3 heparanase SETD2 KDM4A |
| title | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma |
| title_full | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma |
| title_fullStr | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma |
| title_full_unstemmed | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma |
| title_short | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma |
| title_sort | novel therapeutic targets and immune dysfunction in malignant pleural mesothelioma |
| topic | malignant pleural mesothelioma STAT3 heparanase SETD2 KDM4A |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.806570/full |
| work_keys_str_mv | AT moshelapidot noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma AT srinivasvinodsaladi noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma AT srinivasvinodsaladi noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma AT ravisalgia noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma AT martinsattler noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma AT martinsattler noveltherapeutictargetsandimmunedysfunctioninmalignantpleuralmesothelioma |